The microencapsulated formulation of DIM (BioResponse DIM®) contains a minimum of 25% of diindolylmethane. Our 150 mg capsules contain a minimum of 37.5 mg of diindolylmethane. Generic DIM, although it may contain a higher percentage of diindolylmethane, has been shown in studies to be very poorly absorbed.
Please refer to the graph above, which shows the absorption results of a comparison of absorbable BioResponse DIM versus generic DIM. Note that this study compares 300 mg of BioResponse DIM, providing 75 mg diindolylmethane, to a generic DIM capsule, providing 100 mg diindolylmethane.
The BioResponse DIM showed substantially higher absorption values than the generic DIM, even though 25% less diindolylmethane was delivered with this dose of BioResponse DIM. Microencapsulated BioResponse DIM displays much higher absorption, while the generic DIM shows little absorption at all.
Recently, a number of knock-off manufacturers are attempting to position products offering a higher milligram amount of DIM in formulations without addressing the need for an absorption-enhancing microencapsulated formulation. Simply increasing the milligrams of DIM does not result in any predictable absorption. Our formulation is the only DIM formulation shown to shift the estrogen metabolite ratio in clinical studies and provide other benefits in the suggested dose range.
All published clinical studies have only used the BioResponse patented DIM formulation. BioResponse DIM is the only DIM clinically tested in humans and is also the only DIM in clinical trials sponsored by the National Cancer Institute (Visit http://clinicaltrials.gov, keyword:”diindolylmethane”).
LEARN MORE: The Real Facts on Safety: I3C vs DIM... |
